Posters

Accelerated corneal collagen cross-linking in keratoconus patients with Down syndrome

Poster Details

First Author: M.Taskapili TURKEY

Co Author(s):    Y. Yildirim   A. Agca   B. Kepez Yildiz   O. Olcucu   S. Genc   M. Arici     

Abstract Details

Purpose:

To evaluate the effect of accelerated corneal collagen crosslinking (A-CXL) used as a treatment option in Down syndrome patients with progressive keratoconus.

Setting:

Beyoglu Eye Training and Research Hospital

Methods:

Forty-six eyes of 23 Down syndrome patients with progressive keratoconus data were retrospectively reviewed. Thirty-six eyes of 21 patients who intended accelerated (18 mW/cm(2), 365-nm ultraviolet-A light, 5 minutes) collagen crosslinking (CXL) included this study. Main outcome measures were change in keratometry, uncorrected visual acuity (UCVA), and best-corrected visual acuity (BCVA). Also preoperative and postoperative endothelial cell count and central corneal thickness (CCT)were evaluated. All adverse events were also documented.

Results:

The mean age of all patients (10 women and 11 men) was 21.40 �Â�± 4.20 years (range: 18 to 25 years). UDVA improved from 0.70 �Â�± 0.38 to 0.65 �Â�± 0.40 logMAR (P = .062) at the postoperative one year visit. At the last follow-up visit, the flat keratometry decreased from 48.84 �Â�± 3.60 to 48.32 �Â�± 2.92 D, steep keratometry decreased from 53.55 �Â�± 5.12 to 52.86 �Â�± 4.40 D, and apex keratometry decreased from 59.84 �Â�± 5.60 to 59.32 �Â�± 6.50 D (P = .072, = .055, = .060, respectively) from baseline.

Conclusions:

The findings of this study revealed that A-CXL treatment effective and safe option in Down syndrome patients with progressive keratoconus.

Financial Disclosure:

NONE